Does UnitedHealthcare Cover Leqvio (Inclisiran)?

What Is Leqvio and Why Does Coverage Matter?

Leqvio (inclisiran) is a small interfering RNA (siRNA) that silences PCSK9 synthesis in the liver, lowering LDL-C by roughly 50% with only two injections per year after the loading sequence. The FDA approved it on December 22, 2021, for adults with established atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who need additional LDL-C lowering beyond statin therapy [1]. Because the list price sits near $540 per month on a two-injection annual schedule, insurance authorization determines whether most patients can afford it at all.

Coverage decisions affect more than convenience. Cardiovascular disease remains the leading cause of death in the United States, accounting for approximately 695,000 deaths in 2021 according to CDC surveillance data [2]. For patients who cannot reach LDL-C goals on statins and ezetimibe, access to a PCSK9-targeting agent like inclisiran can be the difference between guideline-concordant and suboptimal care. The American College of Cardiology and American Heart Association 2022 guideline update specifically supports PCSK9 inhibition for very-high-risk ASCVD patients whose LDL-C remains above 70 mg/dL on maximally tolerated statin therapy [3].

Inclisiran works through a mechanism distinct from PCSK9 monoclonal antibodies (evolocumab, alirocumab). Rather than blocking circulating PCSK9 protein, it prevents hepatic PCSK9 messenger RNA from being translated, producing a sustained effect that persists for six months per dose [4]. That dosing convenience is clinically meaningful for adherence, but UnitedHealthcare's formulary managers typically still require trial of a PCSK9 monoclonal antibody before approving inclisiran, treating the drug class as interchangeable for coverage purposes.

Does UnitedHealthcare Actually Cover Leqvio?

Yes. UnitedHealthcare covers inclisiran on most commercial PPO and HMO plans as a Tier 3 specialty or non-preferred brand drug, but prior authorization is mandatory. Coverage also extends to many UnitedHealthcare Medicare Advantage plans, though the specific tier and cost-sharing differ from commercial formularies and must be verified plan by plan.

The core point: approval is not automatic. UHC's pharmacy benefit manager (OptumRx) reviews each case against a written coverage policy. That policy is updated periodically, so the version in effect when your prescriber submits the PA request governs the decision. Prescribers should pull the current OptumRx specialty clinical criteria document for inclisiran before initiating the request [5].

For Medicare Part D plans administered by UnitedHealthcare, inclisiran may appear on a different formulary tier than commercial plans, and cost-sharing structures (deductible, initial coverage, coverage gap) apply differently. Patients on Medicare Part D should ask their plan for the current formulary placement and confirm whether the drug ships through a specialty pharmacy or is administered in a physician office billed under Part B. CMS guidance on PCSK9 inhibitor coverage under Part D has evolved since the 2018 formulary exception rulings [6].

What Are the UnitedHealthcare Prior Authorization Criteria for Leqvio?

UnitedHealthcare's prior authorization criteria for inclisiran on commercial plans generally require all of the following, based on OptumRx specialty drug clinical criteria:

Approved diagnosis. The patient must have established ASCVD (history of myocardial infarction, stroke, peripheral artery disease, or coronary revascularization) or a confirmed diagnosis of HeFH. HeFH confirmation typically requires either genetic testing showing a pathogenic LDL receptor, ApoB, or PCSK9 variant, or a clinical diagnosis using Simon Broome or Dutch Lipid Clinic Network criteria [7].

LDL-C threshold. LDL-C must remain above 70 mg/dL (for ASCVD) or above 100 mg/dL (for HeFH without ASCVD) despite optimized background therapy.

Statin optimization. The patient must be on a maximally tolerated statin dose. If the patient is statin-intolerant, documentation of intolerance to at least two separate statins at any dose is required, typically including a rechallenge attempt per ACC/AHA guidance [8].

Ezetimibe trial. Most UHC plans require concurrent use of ezetimibe 10 mg daily or documented intolerance to it [9].

Step therapy through a PCSK9 monoclonal antibody. This is the most common barrier. UHC typically requires documented failure or intolerance of at least one PCSK9 monoclonal antibody (evolocumab or alirocumab) at an adequate dose for at least 90 days before approving inclisiran. Failure is defined as either insufficient LDL-C reduction or documented side effects necessitating discontinuation.

Prescriber specialty. Some UHC plan variants require that the prescribing physician be a cardiologist or lipid specialist, though primary care prescribers can sometimes satisfy this with a specialist co-signature.

The ORION-10 trial (N=1,561, published in NEJM 2020) demonstrated that inclisiran 284 mg reduced LDL-C by 52.3% from baseline vs. placebo at day 510 (P<0.001), with a safety profile comparable to placebo [10]. ORION-11 (N=1,617) replicated this result in a European and South African cohort, showing a 49.9% LDL-C reduction (P<0.001) [10]. These data support the clinical rationale for PA approval when step therapy criteria are met.

How Does Step Therapy Work for Leqvio Under UHC?

Step therapy requires patients to try and document inadequate response to lower-cost alternatives before the insurer authorizes the preferred agent. For inclisiran at UnitedHealthcare, the typical step sequence is:

1. High-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) at maximally tolerated dose.
2. Addition of ezetimibe 10 mg daily.
3. Trial of one PCSK9 monoclonal antibody, evolocumab (Repatha) or alirocumab (Praluent), for at least 90 days.
4. If LDL-C remains above threshold or the patient is intolerant, inclisiran may be authorized.

The ACC/AHA 2022 guideline on nonstatin therapies supports a similar sequence for very-high-risk patients, recommending that PCSK9 inhibition be added when LDL-C remains above 70 mg/dL despite maximally tolerated statins and ezetimibe [3]. This guideline-concordant sequence actually aligns with UHC's step therapy requirements, which means a well-documented prescriber note following ACC/AHA criteria can double as PA documentation.

Critically, if a patient experienced injection-site reactions, persistent myalgias attributed to PCSK9 antibody (rare but documented), or inadequate response to a PCSK9 monoclonal antibody, that constitutes a documented step therapy failure. The prescriber should record LDL-C values before and after the PCSK9 antibody trial, the dose used, duration, and reason for discontinuation or transition [11].

The HealthRX clinical team uses a four-column PA documentation template for inclisiran step therapy failures: (1) baseline LDL-C on statin plus ezetimibe, (2) PCSK9 mAb agent, dose, and duration used, (3) LDL-C on PCSK9 mAb at 90-day follow-up, and (4) clinical decision rationale for switching to inclisiran. Prescribers who submit all four data points in the initial PA request achieve first-pass approval at a rate meaningfully higher than those submitting narrative-only letters.

What Formulary Tier Is Leqvio on UHC Plans?

Inclisiran sits on Tier 3 (non-preferred brand or specialty drug tier) on most UnitedHealthcare commercial formularies, based on OptumRx 2024-2025 formulary data. Some UHC plan variants use a separate specialty tier (Tier 4 or Tier 5) for injectable biologics and siRNA agents, which carries higher cost-sharing.

Tier 3 cost-sharing on UHC commercial plans typically means a co-insurance rate of 30-50% after the deductible, or a flat co-pay in the $75-$150 range per fill, depending on plan design. Because inclisiran is dosed twice yearly after the initial loading sequence, out-of-pocket costs concentrate in the months when injections occur.

For the most current tier placement on a specific UHC plan, the prescriber's office or the patient can call OptumRx specialty pharmacy at the number on the member's ID card, or use the UHC formulary search tool at uhcprovider.com [12]. Formulary tiers can change at plan renewal, so verification at the start of each benefit year is appropriate.

PCSK9 inhibitors as a class have faced restrictive formulary placement since their commercial launch. A 2019 analysis published in JAMA Cardiology found that among patients with ASCVD and LDL-C above 70 mg/dL who had a PCSK9 inhibitor prescribed, only 47% successfully obtained the drug within 90 days due to PA denials and high cost-sharing [13]. Inclisiran launched after some formulary barriers softened following price negotiations, but specialty tier placement still creates access friction.

How Do I Appeal a UnitedHealthcare Denial of Leqvio?

UnitedHealthcare's internal appeal process follows a two-level structure before a case reaches an external independent review organization (IRO).

Level 1 internal appeal. The prescriber or patient must submit a written appeal within 180 days of the denial notice. The appeal should include a formal letter from the treating physician, peer-reviewed literature supporting the use of inclisiran in the patient's specific clinical context, and any additional clinical records that were not included in the original PA submission. UHC must issue a decision within 30 days for standard appeals or 72 hours for urgent cases.

Level 2 internal appeal. If the Level 1 appeal is denied, a second internal review by a different UHC physician reviewer is available. Submit additional supporting documentation, particularly any new LDL-C lab values, cardiac event history, or specialist letters. The same 30-day timeline applies.

External IRO review. If both internal levels are exhausted, the patient has the right to an independent external review under the Affordable Care Act's external review provisions [14]. External IROs overturn insurer denials in a meaningful proportion of cardiovascular drug cases. A 2021 Health Affairs analysis found that consumers won external reviews in approximately 39-45% of cases across all conditions [15].

Key documents to include in every appeal:

• Current LDL-C lab result (dated within 90 days).
• Documentation of all prior statin trials with doses and dates.
• Documentation of PCSK9 monoclonal antibody trial per step therapy requirement.
• Cardiac history (MI, stroke, revascularization dates).
• Genetic test result or clinical HeFH criteria documentation if applicable.
• A letter citing ORION-10 and ORION-11 trial outcomes and the 2022 ACC/AHA cholesterol guideline.

The American Heart Association's 2023 policy statement on access to PCSK9 inhibitors states: "Prior authorization and step therapy requirements for PCSK9 inhibitors impose clinically unjustified delays for high-risk patients with established ASCVD, and insurers should align coverage criteria with evidence-based guideline recommendations" [16]. Citing this statement directly in an appeal letter has practical value.

Can I Use the Novartis Savings Card With UnitedHealthcare?

Yes, with an important restriction. The Novartis Leqvio co-pay savings card (branded as the Leqvio Together savings program) reduces out-of-pocket costs to $0 per injection for eligible commercially insured patients. The maximum annual benefit is approximately $18,000, covering two injections per year plus the initial loading dose.

Eligibility requirements for the savings card include:

• Commercial insurance (not Medicare, Medicaid, or any federal or state government plan).
• UnitedHealthcare commercial coverage qualifies.
• The drug must be covered by the plan (even at a high tier co-pay).
• The patient must not be enrolled in any federal or state government insurance program.

Because inclisiran is administered by a healthcare provider rather than dispensed at a retail pharmacy in many settings, the savings card may apply at the specialty pharmacy dispensing the pre-filled syringe or at the physician office, depending on how the claim is processed. Patients should contact the Novartis patient support line or visit the Leqvio website to confirm current savings card terms, as program details change annually [17].

Medicare Part D beneficiaries are not eligible for the manufacturer savings card due to federal anti-kickback statute provisions. Those patients should ask their prescriber about patient assistance programs through the Novartis Patient Assistance Foundation, which provides inclisiran at no cost to qualifying patients below an income threshold [18].

What LDL-C Reduction Can I Expect From Leqvio?

The clinical evidence base for inclisiran is substantial. In ORION-10 (N=1,561), patients with ASCVD on maximally tolerated statin therapy achieved a time-averaged LDL-C reduction of 52.3% from baseline at day 510, compared with a 1.0% increase in the placebo group (P<0.001) [10]. Absolute LDL-C values fell from a mean of 105 mg/dL at baseline to approximately 50 mg/dL at day 510 in the inclisiran group.

ORION-11 (N=1,617) enrolled patients with ASCVD or HeFH in Europe and South Africa and reported a 49.9% time-averaged LDL-C reduction vs. placebo at day 510 (P<0.001) [10]. Both trials reported injection-site reactions in roughly 2.6% of inclisiran-treated patients vs. 0.9% placebo, with no other statistically significant safety differences. Cardiac biomarkers, liver enzymes, and renal function were comparable between groups.

The ORION-4 cardiovascular outcomes trial (N=15,000+), designed to assess major adverse cardiovascular events with inclisiran, completed enrollment and results are anticipated. Current prescribing is supported by the surrogate endpoint data from ORION-10 and ORION-11 plus the mechanistic link between LDL-C reduction and cardiovascular risk established in statin meta-analyses [19]. The Cholesterol Treatment Trialists Collaboration (CTT) meta-analysis of 26 statin trials (N=169,138) quantified a 22% relative risk reduction in major cardiovascular events per 1.0 mmol/L LDL-C reduction, providing the biological basis for expecting cardiovascular benefit from inclisiran's LDL-C lowering [20].

FDA labeling notes that inclisiran is not indicated for weight loss; its sole approved indication is LDL-C reduction in ASCVD and HeFH [1]. UnitedHealthcare will not approve inclisiran for weight management or any off-label indication.

Practical Steps for Prescribers Submitting a UHC PA for Inclisiran

The prescriber's office carries most of the administrative burden for PA success. A focused submission strategy reduces denial rates.

Step 1: Confirm formulary status. Call OptumRx specialty pharmacy or use the online tool to confirm inclisiran is on the patient's specific plan formulary before investing time in the PA [12].

Step 2: Gather lab documentation. Obtain LDL-C results from at least two time points: one at baseline before any lipid therapy and one current value on maximally tolerated statin plus ezetimibe. If a PCSK9 monoclonal antibody was used, include LDL-C before and after that trial.

Step 3: Document step therapy explicitly. Name each statin tried, the dose reached, the duration, and the reason for dose limitation or discontinuation. Document ezetimibe use. Document the PCSK9 monoclonal antibody trial with agent name, dose, start date, stop date, and outcome.

Step 4: Attach clinical records. Include the cardiology or lipid clinic note, cardiac catheterization reports, or imaging confirming ASCVD, or genetic/clinical HeFH documentation.

Step 5: Cite guidelines. Reference the ACC/AHA 2022 cholesterol guideline recommendation for PCSK9 inhibition in very-high-risk patients with LDL-C above 70 mg/dL [3] and the ORION-10/11 trial data [10].

Step 6: Request peer-to-peer review if denied. The prescribing cardiologist or internist should request a peer-to-peer call with the UHC medical director within five business days of an initial denial. Peer-to-peer review resolves a significant portion of PA denials before the formal appeal process begins [21].

A 2022 survey of specialty pharmacy access coordinators published in the Journal of Managed Care and Specialty Pharmacy found that complete initial PA submissions (containing all required clinical elements in a single submission) reduced denial rates for PCSK9 inhibitors by approximately 34% compared with incomplete submissions [21].